Karyopharm Therapeutics, Inc. (KPTI)

Oncology Corporate Profile

Stock Performance

10.1000
-0.0400

HQ Location

2 Mercer Road
Natick, MA 01760

Company Description

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by blocking the XPO1, preventing the export of various proteins out of the nucleus. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing.

Website: http://www.karyopharm.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
selinexor / KPT-330XPO1 inhibitorAcute Myelogenous Leukemia (AML)III
selinexor (+ decitabine) / KPT-330 XPO1 inhibitorAcute Myelogenous Leukemia (AML)II
selinexor / KPT-330XPO1 inhibitorDiffuse large B-cell Lymphoma (DLBCL)II
KPT-330 XPO1 inhibitorGlioblastoma Multiforme (GBM)II
selinexor / KPT-330XPO1 inhibitorCutaneous T-cell Lymphoma (CTCL)I
selinexor / KPT-330XPO1 inhibitorMultiple MyelomaI
selinexor / KPT-330XPO1 inhibitorPediatric cancerI
selinexor / KPT-330XPO1 inhibitorProstate cancerI
selinexor / KPT-330XPO1 inhibitorSarcomaI
selinexor / KPT-330XPO1 inhibitorVarious cancer typesI

View additional information on product candidates here »

Pipeline image

Source


http://www.karyopharm.com

Recent News Headlines

Karyopharm Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Selinexor Clinical Update

3/16/2017 11:03 am

[GlobeNewswire] - ?Overall Response Rate of 28.4% Observed in Phase 2 b SADAL Study in Relapsed/Refractory DLBCL; Additional Top-line Data to be Presented as a Late-Breaker at AACR 2017 Annual Meeting–. ?Company Announces ...

Karyopharm Announces Partial Clinical Hold to Pause Enrollment in Selinexor Trials

3/11/2017 12:05 am

[GlobeNewswire] - All Currently Enrolled Patients with Stable Disease or Better Can Continue Receiving Selinexor. Company Has Amended Investigator’ s Brochure and Informed Consent Documents as Requested by FDA. Company ...

Karyopharm to Report Fourth Quarter and Year End 2016 Financial Results on March 16, 2017

3/9/2017 01:00 pm

[GlobeNewswire] - NEWTON, Mass., March 09, 2017-- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and year end 2016 financial results and provide ...

Karyopharm Announces Results from Interim Analysis of Phase 2 SOPRA Study Evaluating Selinexor in Relapsed/Refractory Acute Myeloid Leukemia

3/2/2017 09:00 pm

[GlobeNewswire] - Study Will Not Reach Statistically Significant Improvement in Primary Endpoint of Overall Survival in Patients who are Unfit for Chemotherapy and/or Transplantation; Patients Deriving Benefit to Remain ...

Karyopharm Announces the Presentation of New Data at the 2017 American Association for Cancer Research Annual Meeting

3/1/2017 11:00 pm

[GlobeNewswire] - Late-Breaking Presentation Highlighting Interim Phase 2 b Selinexor Data in Patients with Relapsed or Refractory DLBCL. Presentations Include Eleven Preclinical Abstracts Describing Key Scientific Findings ...

Karyopharm to Participate in Upcoming Investor Conferences

1/31/2017 12:03 pm

[GlobeNewswire] - NEWTON, Mass., Jan. 31, 2017-- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that members of the management team will participate in the following upcoming investor ...